和舆

Beijing Heyu Pharmaceutical Technology is a Chinese biopharmaceutical company specializing in the research and development of novel therapeutics for otorhinolaryngology (ear, nose, and throat) disorders and neurological conditions. The company's lead clinical candidate, HY01 (dexamethasone sodium phosphate), is an investigational formulation designed for intratympanic (eardrum) injection to treat sudden sensorineural hearing loss, Ménière's disease, and cholesteatoma. By utilizing a specialized formulation that avoids the use of traditional excipients or support agents, HY01 aims to improve drug stability and bioavailability in the inner ear while minimizing local tissue damage. Additionally, the company is exploring neuroprotective peptide therapies targeting the PSD-95 GK domain for the treatment of ischemic brain injury and neural damage.